Evidence mapPaperPMID 42176263Full record

ArticleAngewandte Chemie (International ed. in English)2026

Perilipin-2-Anchored Lipid Droplet-Targeting Phototheranostics.

Lipeng Zhang, Jiyoung Yoo, Juan Bai, Sunghyun Kim, Yesim Bakan, Yongbin Zhang, Fangjun Huo, Jingying Zhou, Caixia Yin, Jong Seung Kim

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lipeng ZhangKey Laboratory of Chemical Biology and Molecular Engineering of the Ministry of Education, Biomedical and Health Laboratory in Shanxi Province, Research Institute of Applied Chemistry, Shanxi University, Taiyuan, China.
Jiyoung YooDepartment of Chemistry, Korea University, Seoul, Republic of Korea.
Juan BaiKey Laboratory of Chemical Biology and Molecular Engineering of the Ministry of Education, Biomedical and Health Laboratory in Shanxi Province, Research Institute of Applied Chemistry, Shanxi University, Taiyuan, China.
Sunghyun KimDepartment of Chemistry, Korea University, Seoul, Republic of Korea.
Yesim BakanDepartment of Chemistry, Korea University, Seoul, Republic of Korea.
Yongbin ZhangKey Laboratory of Chemical Biology and Molecular Engineering of the Ministry of Education, Biomedical and Health Laboratory in Shanxi Province, Research Institute of Applied Chemistry, Shanxi University, Taiyuan, China.
Fangjun HuoKey Laboratory of Chemical Biology and Molecular Engineering of the Ministry of Education, Biomedical and Health Laboratory in Shanxi Province, Research Institute of Applied Chemistry, Shanxi University, Taiyuan, China.
Jingying ZhouSchool of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Caixia YinKey Laboratory of Chemical Biology and Molecular Engineering of the Ministry of Education, Biomedical and Health Laboratory in Shanxi Province, Institute of Molecular Science, Shanxi University, Taiyuan, China.ORCID https://orcid.org/0000-0001-5548-6333
Jong Seung KimDepartment of Chemistry, Korea University, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-3477-1172

Funding

2024 Three-Jin Talents Program-Project in the Field of Innovation and TechnologyNational Natural Science Foundation of China 22325703National Natural Science Foundation of China 22377072National Natural Science Foundation of China U23A6009National Natural Science Foundation of China U25A20593National Research Foundation of Korea 2018R1A3B1052702National Research Foundation of Korea RS-2025-16652968Research Project Supported by Shanxi Scholarship Council of China 2022-002Shanxi Province science and technology activities for overseas people selected funding project 2024001Shanxi Province Science Foundation 202203021221009
6 · The paper itself

Abstract

Conventional photothermal agents are readily taken up by normal cells, which may cause off-target damage. Lipid droplet (LD) targeting can enable photothermal agents to accumulate in tumor cells enriched in LDs, a central hub for lipid storage. We herein report an LD-targeted theranostic agent, C-BDP-OMe, through a dual-anchoring strategy that combines the principle of "like dissolves like" with specific docking to the PLIN2 protein. Structurally, C-BDP-OMe features an extended conjugated system and an asymmetric coumarin-fused BODIPY scaffold, enabling NIR-region optical properties, a large Stokes shift, and high photostability. The probe exhibits polarity-sensitive behavior, with turn-on fluorescence and a high signal-to-noise ratio under no-wash conditions. Furthermore, C-BDP-OMe demonstrates robust photothermal performance, with a photothermal conversion efficiency of 62.6%, enabling localized photothermal ablation and resulting in effective tumor suppression while avoiding systemic side effects. The therapeutic mechanism was systematically investigated and shown to involve the concurrent activation of two distinct cell death pathways-apoptosis and ferroptosis. This work highlights the therapeutic value of subcellular organelle-level precision interventions and underscores the importance of exploiting subtle microenvironmental features in the design of next-generation anticancer theranostic agents.

Indexed as

Antineoplastic AgentsLipid DropletsPerilipin-2Theranostic NanomedicineAnimalsBoron CompoundsCoumarinsHumans4,4-difluoro-4-bora-3a,4a-diaza-s-indaceneAntineoplastic AgentsBoron CompoundsCoumarinsPerilipin-2coumarin‐fused BODIPYdual‐anchoringfluorescence imaginglipid dropletsphotothermal therapy

Identifiers

PMID42176263
PMCPMC13383187

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.